Evidence map›Paper›PMID 40568000›Full record

ArticleOpen forum infectious diseases2025

Switching From Dual to Monotherapy for Gonorrhea is Associated With a Halving of Gonococcal Resistance to Azithromycin-A Modelling Study of MSM in Belgium.

Achilleas Tsoumanis, Christophe Van Dijck, Niel Hens, Chris Kenyon

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Heterogeneity of azithromycin resistance markers inNew microbes and new infections · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Achilleas TsoumanisDepartment of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0001-7565-1359
Christophe Van DijckDepartment of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0001-8010-1351
Niel HensCentre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-1881-0637
Chris KenyonDepartment of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-2557-8998

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We developed a network-based model for CT and NG transmission among MSM in Belgium to estimate the prevalence of CT, NG, and AR-NG in the population. The model simulates transmission of NG among 3 anatomical sites in a population of 10 000 MSM over 10 years. The effect of different treatment strategies was evaluated in terms of CT, NG, and AR-NG prevalence as well as antibiotic consumption. Results: Our model captured adequately well the observed azithromycin-resistance epidemic over a 10-year period in Belgium, with AR-NG increasing from 0% to 44%. Antibiotic consumption, and prevalences of NG and AR-NG decreased when ceftriaxone monotherapy was used against NG, while CT prevalence increased, compared to dual therapy. In the ceftriaxone monotherapy scenario, the prevalence of AR-NG was approximately half of that in the dual-therapy scenario (23%). Conclusions: Switching from dual to monotherapy was associated with a halving of the prevalence of AR-NG. These results provide further evidence to favor mono- over dual therapy for the treatment of gonorrhea.

Indexed as

antimicrobial resistancechlamydia trachomatismathematical modelmen who have sex with menneisseria gonorrhoeae

Identifiers

PMID40568000
PMCPMC12188198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.